Shares of Sun Pharma Advanced Research Company Ltd (SPARC) plunged nearly 20% on Wednesday on the NSE, after the company ...

SPARC tumbled 19 percent after Phase 2 trials of its psoriasis drug SCD-044 failed to meet primary endpoints. The company ...

SPARC share price plunged 20% following poor Phase 2 trial outcomes for SCD-044. The stock peaked at ₹186 but fell to ₹156.50 during trading on the BSE.

Before you try one, even an over-the-counter product, talk to your doctor. Some people with psoriasis notice that their symptoms improve after they’ve spent time in the sun. How It May Help ...

Sun chose to address the impact of psoriasis beyond its sometimes “unbearable” physical symptoms after speaking to Ilumya ... trying a variety of treatments before finding one that works ...

Sun Pharma launched ... moderate-to-severe plaque psoriasis. In a press release, Garfunkel said, “With support from my wife, Kim, and a treatment I trust, I am finally ready to give my history with ...